Patents Assigned to Biomed
-
Patent number: 11578119Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.Type: GrantFiled: June 7, 2021Date of Patent: February 14, 2023Assignees: MedImmune LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
-
Patent number: 11576962Abstract: The present invention provides a fusion polypeptide that induces a humoral immune response and a cellular immune response to a virus, containing antigens or fragments thereof of the following (a) and (b), and having an oligomerization activity: (a) an antigen of the virus or a fragment thereof containing a B cell epitope conserved among subtypes of the virus; and (b) an antigen of the virus or a fragment thereof containing a T cell epitope conserved among subtypes of the virus (wherein the antigen(s) or the fragment(s) thereof of (a) and/or (b) have an oligomerization activity, or the fusion polypeptide further contains (c) a polypeptide having an oligomerization activity in addition to the antigens or the fragments thereof (a) and (b)).Type: GrantFiled: December 21, 2018Date of Patent: February 14, 2023Assignee: Green BioMed, Inc.Inventor: Kenji Sekikawa
-
Patent number: 11578333Abstract: The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.Type: GrantFiled: March 8, 2021Date of Patent: February 14, 2023Assignee: SNIPR Biome ApSInventors: Virginia Martinez, Ruben Vazquez-Uribe, Adam Takos, Eric Van Der Helm, Jasper Clube
-
Publication number: 20220411513Abstract: Provided is an anti-PD-L1 antigen binding protein, capable of binding to primate-derived PD-L1 with a KD value of 1×10?8 M or less. The antigen binding protein can block the binding of PD-1 and CD80 to PD-L1, stimulate the secretion of cytokines in immune cells, and can inhibit tumor growth and/or tumor cell proliferation. Also provided is a fusion protein, comprising human TGFBRII or a fragment thereof and the antigen binding protein. Also provided is an application of the antigen binding protein and/or the fusion protein in the prevention and treatment of tumors or cancers.Type: ApplicationFiled: September 29, 2020Publication date: December 29, 2022Applicant: Harbour BioMed (Shanghai) Co., LtdInventors: Yun HE, Shuwen REN, Bin LIU, Xin GAN, Donghai LI, Fei CHEN, Ling WANG, Jin LI, Yiping RONG
-
Patent number: 11534191Abstract: A loading device for loading a medical device into a catheter is provided. The loading device comprises a body having a lumen to receive an expandable portion of a medical device. The lumen has a length as the expandable portion when the latter is in a collapsed configuration and has a diameter that is greater than the collapsed configuration. The body comprises a first portion and a second portion that are reversibly separable to expose the lumen in an open configuration and enclose the lumen in a closed configuration. The first and second portions each comprise an inner face having a groove defining a first portion of the lumen and a second portion of the lumen, respectively. The body also has a distal tip portion to reversibly couple with a hemostatic valve of a delivery catheter. A method of loading a medical device into a catheter is also provided.Type: GrantFiled: December 24, 2019Date of Patent: December 27, 2022Assignee: Anaconda Biomed, S.L.Inventors: Robert Ros Fàbrega, Iñaki Galve Murillo, Ofir Arad Hadar, Ane Lizarazu Gonzalez
-
Patent number: 11534487Abstract: The present invention provides a fusion polypeptide that induces a humoral immune response and a cellular immune response to a virus, containing antigens or fragments thereof of the following (a) and (b), and having an oligomerization activity: (a) an antigen of the virus or a fragment thereof containing a B cell epitope conserved among subtypes of the virus; and (b) an antigen of the virus or a fragment thereof containing a T cell epitope conserved among subtypes of the virus (wherein the antigen(s) or the fragment(s) thereof of (a) and/or (b) have an oligomerization activity, or the fusion polypeptide further contains (c) a polypeptide having an oligomerization activity in addition to the antigens or the fragments thereof (a) and (b)).Type: GrantFiled: December 21, 2018Date of Patent: December 27, 2022Assignee: Green BioMed, Inc.Inventor: Kenji Sekikawa
-
Patent number: 11512138Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: March 18, 2020Date of Patent: November 29, 2022Assignees: The United States of America, as Presented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha
-
Publication number: 20220363781Abstract: Related are an anti-TSLP antibody or an antigen-binding fragment thereof, nucleic acid molecules coding the same, and a method for preparing the same. The anti-TSLP antibody or the antigen-binding fragment thereof have high affinity to TSLP, capable of effectively binding with TSLP and blocking the proliferative effect of TSLP with respect to Ba/F3-hTSLPR-hIL7R? cells, and blocking the capability of TSLP in activating and secreting cytokines with respect to PBMC. At the same time, further related are a medicinal composition comprising the antibody or the antigen-binding fragment thereof, and uses of the composition in preparing a medicament for preventing and/or treating asthma, allergic inflammation, an allergic reaction or autoimmune disease.Type: ApplicationFiled: December 8, 2020Publication date: November 17, 2022Applicants: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., Harbour Biomed (Suzhou) Co., Ltd.Inventors: Liang XIAO, Jinqiu HE, Tongtong XUE, Hongshui LIU, Jingyi WANG, Hongzhuan GU, Shuntao LUO, Yiping RONG, Dengnian LIU, Yun HE
-
Publication number: 20220348652Abstract: Disclosed herein are recombinant antibodies exhibiting binding affinity to CD47 polypeptide. According to some embodiments of the present disclosure, the recombinant antibodies are capable of blocking the interaction of CD47 and signal receptor protein-alpha (SIRP?). Accordingly, also disclosed herein are pharmaceutical compositions comprising the recombinant antibodies, and uses thereof in the treatment CD47-related diseases.Type: ApplicationFiled: April 22, 2022Publication date: November 3, 2022Applicant: AnTaimmu BioMed Co., Ltd.Inventors: San-Tai SHEN, Yueh-Liang TSOU, Jen-Chieh LIN, Chia-Chi LIU
-
Patent number: 11484611Abstract: A method for sterilizing biological materials is disclosed. A dehydrated biological material is put into a closed container. The closed container is then decompressed under a vacuum. Subsequently, 0.01 g/m3 to 1000 g/m3 of a sterilizing gas, i.e., pure ozone, is introduced into the container for a period of time until the biological material is sterilized.Type: GrantFiled: March 19, 2019Date of Patent: November 1, 2022Assignee: FM&G Biomed Co., Ltd.Inventor: Lynn L. H. Huang
-
Patent number: 11485973Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: GrantFiled: September 23, 2020Date of Patent: November 1, 2022Assignee: SNIPR Biome ApSInventors: Morten Sommer, Virginia Martinez, Eric Van der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
-
Publication number: 20220290133Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: ApplicationFiled: May 19, 2022Publication date: September 15, 2022Applicant: SNIPR Biome ApSInventors: Morten SOMMER, Virginia MARTINEZ, Eric VAN DER HELM, Jakob Krause HAABER, Ana DE SANTIAGO TORIO, Christian GRØNDAHL, Jasper CLUBE
-
Publication number: 20220282245Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: ApplicationFiled: May 20, 2022Publication date: September 8, 2022Applicant: SNIPR Biome ApSInventors: Morten SOMMER, Virginia MARTINEZ, Eric VAN DER HELM, Jakob Krause HAABER, Ana DE SANTIAGO TORIO, Christian GRØNDAHL, Jasper CLUBE
-
Publication number: 20220275380Abstract: The invention relates to means for carrying out conjugation between bacteria, and in particular the invention relates to carrier (ie, donor) bacteria comprising antimicrobial agents and methods of use. A carrier bacterium is capable of conjugative transfer of DNA encoding the agent to a target cell (ie, recipient cell). The invention provides novel plasmids that are devoid a functional hypC2 nucleotide sequence for these purposes.Type: ApplicationFiled: August 21, 2020Publication date: September 1, 2022Applicant: SNIPR Biome ApSInventor: Andreas PORSE
-
Patent number: 11421227Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: GrantFiled: March 11, 2021Date of Patent: August 23, 2022Assignee: SNIPR Biome ApSInventors: Morten Sommer, Virginia Martinez, Eric Van Der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
-
Publication number: 20220259588Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: ApplicationFiled: April 25, 2022Publication date: August 18, 2022Applicant: SNIPR Biome ApSInventors: Morten SOMMER, Virginia MARTINEZ, Eric VAN DER HELM, Jakob Krause HAABER, Ana DE SANTIAGO TORIO, Christian GRØNDAHL, Jasper CLUBE
-
Publication number: 20220257838Abstract: This disclosure relates to scaffolds made of a braid of bioabsorbable polymeric fibers for implantation within a lumen of a mammalian body and, in particular, to such scaffolds that are configured to divert blood flow from a pathology associated with a blood vessel.Type: ApplicationFiled: May 6, 2022Publication date: August 18, 2022Applicant: Fluid Biomed Inc.Inventors: Alim P. Mitha, John H. Wong
-
Publication number: 20220227843Abstract: The present invention provides binding molecules, including monoclonal antibodies, multi-specific antibodies, and antibody fragments, that specifically bind to the coronavirus, such as SARS-CoV-2, and methods of use thereof. In some aspects of the invention, the binding molecules are human antibodies, fragments, or derivatives thereof that specifically bind to SARS-CoV-2 spike protein. In some aspects of the invention, the binding molecules function to neutralize SARS-CoV-2. The present invention also relates to methods of using the binding molecules and compositions for diagnosis and treatment.Type: ApplicationFiled: January 12, 2022Publication date: July 21, 2022Applicant: Antaimmu BioMed Co., Ltd.Inventors: San-Tai Shen, Ing-Chien Chen, Kuang-Kai Liu, Frederick Y. Luh
-
Patent number: 11390600Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.Type: GrantFiled: July 7, 2020Date of Patent: July 19, 2022Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals IncorporatedInventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
-
Patent number: D974922Type: GrantFiled: May 11, 2021Date of Patent: January 10, 2023Assignee: Biom Innovations Inc.Inventors: Will Gahagan, Hank Schellenger